Back to Search
Start Over
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
- Source :
- Clinical and Molecular Hepatology, Vol 27, Iss 3, Pp 402-412 (2021)
- Publication Year :
- 2021
- Publisher :
- Korean Association for the Study of the Liver, 2021.
-
Abstract
- Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
Details
- Language :
- English
- ISSN :
- 22872728, 2287285X, and 10448268
- Volume :
- 27
- Issue :
- 3
- Database :
- Directory of Open Access Journals
- Journal :
- Clinical and Molecular Hepatology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.10448268416c4ebbb8589720693b347f
- Document Type :
- article
- Full Text :
- https://doi.org/10.3350/cmh.2021.0179